Searching in Pharma & Drug Safety · Search everything
2,977 changes Pharma & Drug Safety
Cell Reprogramming Patent, Asgard Therapeutics, 14th Apr
Cell Reprogramming Patent, Asgard Therapeutics, 14th Apr
Replication-Competent Recombinant HSV-1 With ICP6/IR Deletions for Cancer Treatment
USPTO granted Patent US12600955B1 to Sungkwang Medical Foundation for a replication-competent recombinant herpes simplex virus type 1 (HSV-1) with simultaneous deletions in the ICP6 and IR regions. The patent covers the recombinant HSV-1, vector, and methods of preparation for cancer treatment as an oncolytic virus. The invention enables larger foreign gene insertion and simultaneous multiple gene insertion while maintaining safety and cancer cell killing efficacy.
Modified Double-Stranded Oligonucleotide Patent - Alnylam Pharmaceuticals
USPTO granted patent US12600965B2 to Alnylam Pharmaceuticals, Inc. covering modified double-stranded RNA (dsRNA) agents capable of inhibiting target gene expression. The patent, filed November 5, 2019, includes 38 claims and covers pharmaceutical compositions comprising these dsRNA molecules for therapeutic applications. Inventors include Donald Foster, Mark K. Schlegel, and Christopher Brown.
Viral and Non-Viral Nanoplasmid Vectors with Improved Production
USPTO granted patent US12600984B2 to Aldevron, L.L.C. covering methods for improving replication of covalently closed circular plasmids through replacement of Pol I-dependent origins with Pol III-dependent origins. The patent also claims antibiotic marker free covalently closed circular recombinant DNA molecules. The patent contains 31 claims.
Compositions and Methods for Controlling Production of Polypeptides in Cells
USPTO granted Patent US12600985B2 to the Board of Trustees of the Leland Stanford Junior University on April 14, 2026. The patent covers recombinant expression vectors with coding sequences flanked by recombinase recognition sites for modulating polypeptide production in target cells, along with associated methods and monitoring devices. Inventors include Karl A. Deisseroth, Charu Ramakrishnan, Yoon Seok Kim, and Lief E. Fenno. The patent contains 25 claims under CPC Classification C12N 15/85.
Tetracyclic DGK Inhibitor Compounds for Cancer Treatment
USPTO granted Patent US12600722B2 to Incyte Corporation for tetracyclic compounds that modulate diacylglycerol kinase (DGK) activity, useful in treating cancer including solid tumors. The patent names Joshua Hummel, Shicheng Shi, and Xiaozhao Wang as inventors and contains 63 claims.
ONO Pharmaceutical ABHD6 Antagonist Patent US12600730B2
USPTO granted Patent US12600730B2 to ONO Pharmaceutical Co., Ltd. on April 14, 2026, covering substituted cyclopenta[c]pyrrole compounds as ABHD6 antagonists for pharmaceutical use. The patent includes 18 claims for compounds useful in preventing or treating diseases associated with ABHD6 enzyme inhibition. The application was filed on April 8, 2024.
Interleukin-17 Inhibitors Patent - Novartis AG
The USPTO granted patent US12600728B2 to NOVARTIS AG covering novel pyridine-N oxide substituted 2-formamido (N-phenyl and N-pyridyl) acetamide compounds as Interleukin-17 (IL-17) inhibitors. The patent also protects processes for preparing these compounds, pharmaceutical compositions, and medicaments for treating diseases and disorders mediated by IL-17.
Nanjing University of Chinese Medicine - US12600724B2 Indole Alkaloid Compound and Preparation Method
The USPTO granted Patent US12600724B2 to Nanjing University of Chinese Medicine for an indole alkaloid compound represented by formula (I), including its preparation method and pharmaceutical salts. The compound has demonstrated therapeutic effects in animal studies, including promoting axon growth in peripheral sensory neurons, improving nerve conduction velocity in diabetic rats, accelerating foot ulcer wound healing, reducing pulmonary fibrosis, and protecting lung tissues. The patent contains 13 claims covering the compound, formulations, and methods of treatment for diabetic complications.